Business
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 Raises 2028 Revenue Outlook from $500 Million to $700 Million
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nPortfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025\n\n\n\nRaises 2028 Revenue Outlook from $500 Million to $700 Million\nRepresenting a 29% CAGR\n\n\n\nHighly Capital Efficient Deal Structure Funded Through $50 Million Pharmakon Tranche; Company Expects to Remain Fully Funded to Profitability\n\n\n\nSymatese, with 25 Years of Experience, Developed the XpresHAn Technology™/OBT® for the Latest Generation Restylane® HA Products\n\n\n\n \n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers currently in late-stage development. The addition of a filler line expands the company’s total addressable U.S. market by 70%1 by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market, with both markets expected to nearly double by 20281. As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million.\n\n\n“Today’s announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company,” said David Moatazedi, Evolus’ President and Chief Executive Officer. “We are excited to expand our portfolio with Evolysse™, a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau®. Injectables are the cornerstone of aesthetics with neurotoxins and dermal fillers as the top two aesthetic procedures in the U.S. Our customer-centric approach, existing digital infrastructure and distribution platform will power the launch of this innovative filler technology into the hands of our customers and their patients.”\n\n\nMoatazedi continued, “We are honored to partner with Symatese to introduce the Evolysse™ line to our U.S. customers beginning with the expected launch of the first two indications in the first half of 2025, followed by a third in 2026 and two more in 2027. Once fully launched, the Evolysse™ portfolio will offer a complete range of filler solutions to cover the spectrum of indications including mid-face, nasolabial folds, lips and eyes.\n\n\n“From a finan...